Concepedia

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

D.J. Boote, Ian F. Dennis, P R Twentyman, Richard J. Osborne, C. LABURTE, S. Hensel, J F Smyth, MH Brampton, N M Bleehen

Journal of Clinical Oncology · 1996 · 176 citations · 17 references

DOI

Abstract

PSC 833 can be administered in combination with etoposide with acceptable toxicity. The recommended continuous infusion dose of PSC 833 for this schedule is 10 mg/kg/d over 5 days. PSC 833 results in an increase in etoposide exposure and etoposide doses should be reduced in patients receiving PSC 833.

References

17

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

F Thiébaut, T Tsuruo, Hironobu Hamada et al. · Proceedings of the National Academy of Sciences · 1987 · 2.8K citations · Full text

, , +18

Expression of a multidrug-resistance gene in human tumors and tissues.

Antonio Tito Fojo, Kazumitsu Ueda, Dennis J. Slamon et al. · Proceedings of the National Academy of Sciences · 1987 · 1.6K citations · Full text

, , +16

Expression of Multidrug Resistance Gene in Human Cancers

Lori J. Goldstein, Hanan Galski, Antonio Tito Fojo et al. · JNCI Journal of the National Cancer Institute · 1989 · 1.3K citations

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

Preet M. Chaudhary, Igor B. Roninson · Cell · 1991 · 956 citations

, , +11

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

William S. Dalton, Thomas M. Grogan, Paul S. Meltzer et al. · Journal of Clinical Oncology · 1989 · 560 citations

, , +17